menu
    • menu

    Find Vismodegib manufacturers, exporters & distributors on PharmaCompass

    Polpharma Vismodegib

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    9

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    0

    NDC API

    NDC API

    0

    VMF

    NDC API

    9

    Listed Suppliers

    Other Suppliers

    3INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    8

    FDF Dossiers

    FDF Dossiers

    1

    FDA Orange Book

    FDA (Orange Book)

    4

    Europe

    Europe

    1

    Canada

    Canada

    1

    Australia

    Australia

    1

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    1DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    112RELATED EXCIPIENT COMPANIES

    162EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    3

    US Patents

    0

    US Exclusivities

    1

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 33,031

    GLOBAL SALES INFORMATION

    US Medicaid

    124,771,563

    Annual Reports

    869

    Regulatory FDF Prices

    Listed Dossiers
    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    2

    API

    1

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    5

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 879085-55-9, Gdc-0449, Erivedge, 2-chloro-n-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Vismodegib (gdc-0449), Hhantag691
    Molecular Formula
    C19H14Cl2N2O3S
    Molecular Weight
    421.3  g/mol
    InChI Key
    BPQMGSKTAYIVFO-UHFFFAOYSA-N
    FDA UNII
    25X868M3DS
    Vismodegib
    Vismodegib is an orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.
    Vismodegib is a Hedgehog Pathway Inhibitor. The mechanism of action of vismodegib is as a Smoothened Receptor Antagonist.
    1 2D Structure

    Vismodegib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide
    2.1.2 InChI
    InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)
    2.1.3 InChI Key
    BPQMGSKTAYIVFO-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    25X868M3DS
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Erivedge

    2. Gdc 0449

    3. Gdc-0449

    4. Gdc0449

    5. Hhantag691

    6. Nsc 747691

    7. Nsc-747691

    8. Nsc747691

    9. R 3616

    10. R-3616

    11. R3616 Cpd

    12. Rg 3616

    13. Rg-3616

    14. Rg3616

    2.3.2 Depositor-Supplied Synonyms

    1. 879085-55-9

    2. Gdc-0449

    3. Erivedge

    4. 2-chloro-n-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide

    5. Vismodegib (gdc-0449)

    6. Hhantag691

    7. Gdc0449

    8. Gdc 0449

    9. Gdc-0449 (vismodegib)

    10. Nsc-747691

    11. Nsc-755986

    12. 2-chloro-n-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide

    13. Chembl473417

    14. Chebi:66903

    15. 2-chloro-n-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide

    16. 25x868m3ds

    17. Nsc755986

    18. 2-chloro-n-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide

    19. 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide

    20. 2-chloro-n-(4-chloro-3-pyridin-2-yl-phenyl)-4-methanesulfonyl-benzamide

    21. 2-chloro-n-[4-chloro-3-(pyridin-2-yl)phenyl]-4-methanesulfonylbenzamide

    22. Benzamide, 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-

    23. 2-chloranyl-~{n}-(4-chloranyl-3-pyridin-2-yl-phenyl)-4-methylsulfonyl-benzamide

    24. Erivedge (tn)

    25. Vismodegib [usan]

    26. Vismodegib [usan:inn]

    27. Nsc 747691

    28. Vismodegibum

    29. Unii-25x868m3ds

    30. Hsdb 8130

    31. R 3616

    32. Nsc747691

    33. Hh-antag691

    34. Hhantag 691

    35. Vismodegib, Free Base

    36. Rg 3616

    37. Rg-3616

    38. Methanesulfonylbenzamide

    39. Vismodegib [mi]

    40. Vismodegib [inn]

    41. Vismodegib (usan/inn)

    42. Vismodegib [vandf]

    43. Vismodegib; Gdc-0449

    44. R-3616

    45. Vismodegib [who-dd]

    46. Gdc-0449 - Selumetinib

    47. Mls006012035

    48. Schembl302587

    49. Gtpl6975

    50. Vismodegib [orange Book]

    51. Cur-691

    52. Dtxsid40236689

    53. Gdc-449

    54. Bcpp000223

    55. Hms3604k16

    56. Hms3654e17

    57. Bcp01715

    58. Ex-a2178

    59. Bdbm50249522

    60. Mfcd12407408

    61. Nsc755809

    62. S1082

    63. Zinc40899447

    64. Gdc-0449,vismodegib, Hhantag691

    65. 2-chloro-n-(4-chloro-3-(pyridin-2-yl)-phenyl)-4-(methylsulfonyl)benzamide

    66. Akos015966534

    67. Bcp9000713

    68. Ccg-264811

    69. Cs-0255

    70. Db08828

    71. Nsc-755809

    72. Pb15086

    73. Ncgc00242497-01

    74. Ncgc00242497-02

    75. Ncgc00242497-06

    76. Ncgc00242497-12

    77. Ac-26969

    78. As-14066

    79. Hy-10440

    80. Smr004703564

    81. Ft-0675833

    82. Sw218087-2

    83. Ec-000.2333

    84. D09992

    85. V-4050

    86. Ab01565813_02

    87. 085g559

    88. Sr-01000941574

    89. 2-chloro-n-[4-chloro-3-(pyridin-2-yl)phenyl]-4-

    90. J-509076

    91. Q2070286

    92. Sr-01000941574-1

    93. C538724000

    94. 2-chloro-n-(4-chloro-3-(2-pyridl)phenyl)-4-(methylsulfonyl)benzamide

    95. 2-chloro-n-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methyl Sulfonyl)benzamide

    96. 2-chloro-n~1~-[4-chloro-3-(2-pyridyl)phenyl]-4-(methylsulfonyl)benzamide

    97. 2-chloro-n-(4-chloro-3-pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide

    98. 2-chloro-n-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)-benzamide

    99. Vis

    2.4 Create Date
    2008-05-12
    3 Chemical and Physical Properties
    Molecular Weight 421.3 g/mol
    Molecular Formula C19H14Cl2N2O3S
    XLogP33.8
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count4
    Exact Mass420.0102189 g/mol
    Monoisotopic Mass420.0102189 g/mol
    Topological Polar Surface Area84.5 Ų
    Heavy Atom Count27
    Formal Charge0
    Complexity625
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameErivedge
    PubMed HealthVismodegib (By mouth)
    Drug ClassesAntineoplastic Agent
    Drug LabelVismodegib is an inhibitor of the hedgehog (Hh) signaling pathway, which is described chemically as 2-Chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide. The molecular formula is C19H14Cl2N2O3S. The molecular weight is 421.30 g/mo...
    Active IngredientVismodegib
    Dosage FormCapsule
    RouteOral
    Strength150mg
    Market StatusPrescription
    CompanyGenentech

    2 of 2  
    Drug NameErivedge
    PubMed HealthVismodegib (By mouth)
    Drug ClassesAntineoplastic Agent
    Drug LabelVismodegib is an inhibitor of the hedgehog (Hh) signaling pathway, which is described chemically as 2-Chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide. The molecular formula is C19H14Cl2N2O3S. The molecular weight is 421.30 g/mo...
    Active IngredientVismodegib
    Dosage FormCapsule
    RouteOral
    Strength150mg
    Market StatusPrescription
    CompanyGenentech

    4.2 Therapeutic Uses

    Erivedge capsule is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. /Included in US product label/

    US Natl Inst Health; DailyMed. Current Medication Information for ERIVEDGE (vismodegib) capsule (January 2012). Available from, as of March 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a

    4.3 Drug Warning

    /BOXED WARNING/ WARNING: EMBRYO-FETAL DEATH AND SEVERE BIRTH DEFECTS ERIVEDGE (vismodegib) capsule can result in embryo-fetal death or severe birth defects. Erivedge is embryotoxic and teratogenic in animals. Teratogenic effects included severe midline defects, missing digits, and other irreversible malformations. Verify pregnancy status prior to the initiation of Erivedge. Advise male and female patients of these risks. Advise female patients of the need for contraception and advise male patients of the potential risk of Erivedge exposure through semen.

    US Natl Inst Health; DailyMed. Current Medication Information for ERIVEDGE (vismodegib) capsule (January 2012). Available from, as of March 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a

    Advise patients not to donate blood or blood products while receiving Erivedge and for at least 7 months after the last dose of Erivedge.

    US Natl Inst Health; DailyMed. Current Medication Information for ERIVEDGE (vismodegib) capsule (January 2012). Available from, as of March 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a

    Dysregulated hedgehog signaling is the pivotal molecular abnormality underlying basal-cell carcinomas. Vismodegib is a new orally administered hedgehog-pathway inhibitor that produces objective responses in locally advanced and metastatic basal-cell carcinomas. /The researchers/ tested the anti-basal-cell carcinoma efficacy of vismodegib in a randomized, double-blind, placebo-controlled trial in patients with the basal-cell nevus syndrome at three clinical centers from September 2009 through January 2011. The primary end point was reduction in the incidence of new basal-cell carcinomas that were eligible for surgical resection (surgically eligible) with vismodegib versus placebo after 3 months; secondary end points included reduction in the size of existing basal-cell carcinomas. In 41 patients followed for a mean of 8 months (range, 1 to 15) after enrollment, the per-patient rate of new surgically eligible basal-cell carcinomas was lower with vismodegib than with placebo (2 vs. 29 cases per group per year, P<0.001), as was the size (percent change from baseline in the sum of the longest diameter) of existing clinically significant basal-cell carcinomas (-65% vs. -11%, P=0.003). In some patients, all basal-cell carcinomas clinically regressed. No tumors progressed during treatment with vismodegib. Patients receiving vismodegib routinely had grade 1 or 2 adverse events of loss of taste, muscle cramps, hair loss, and weight loss. Overall, 54% of patients (14 of 26) receiving vismodegib discontinued drug treatment owing to adverse events. At 1 month, vismodegib use had reduced the hedgehog target-gene expression by basal-cell carcinoma by 90% (P<0.001) and diminished tumor-cell proliferation, but apoptosis was not affected. No residual basal-cell carcinoma was detectable in 83% of biopsy samples taken from sites of clinically regressed basal-cell carcinomas. Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with the basal-cell nevus syndrome. The adverse events associated with treatment led to discontinuation in over half of treated patients. Comment in The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version. Destroy user interface controlVismodegib in advanced basal-cell carcinoma.

    PMID:22670904 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362529 Tang JY et al; N Engl J Med 366 (23): 2180-8 (2012)

    FDA Pregnancy Risk Category: D /POSITIVE EVIDENCE OF RISK. Studies in humans, or investigational or post-marketing data, have demonstrated fetal risk. Nevertheless, potential benefits from the use of the drug may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective./

    US Natl Inst Health; DailyMed. Current Medication Information for ERIVEDGE (vismodegib) capsule (January 2012). Available from, as of March 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a

    For more Drug Warnings (Complete) data for Vismodegib (8 total), please visit the HSDB record page.

    4.4 Drug Indication

    Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.

    FDA Label

    Erivedge is indicated for the treatment of adult patients with:

    - symptomatic metastatic basal cell carcinoma

    - locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Vismodegib selectively binds to and inhibits the transmembrane protein Smoothened homologue (SMO) to inhibit the Hedgehog signalling pathway.

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    VISMODEGIB
    5.2.2 FDA UNII
    25X868M3DS
    5.2.3 Pharmacological Classes
    Smoothened Receptor Antagonists [MoA]; Hedgehog Pathway Inhibitor [EPC]
    5.3 ATC Code

    L01XX43

    L01XX43

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01X - Other antineoplastic agents

    L01XJ - Hedgehog pathway inhibitors

    L01XJ01 - Vismodegib

    5.4 Absorption, Distribution and Excretion

    Absorption

    The absolute bioavailability of a single dose is 31.8%. Absorption is saturable and is not affected by food.

    Route of Elimination

    Vismodegib is mostly excreted unchanged, and the main route of elimination is by the feces (82%) and the urine accounts for 4.4%.

    Volume of Distribution

    Vismodegib has a volume of distribution of 16.4 to 26.6 L.

    The volume of distribution of vismodegib ranges from 16.4 to 26.6 L. Vismodegib plasma protein binding in patients is greater than 99%. Vismodegib binds to both human serum albumin and alpha-1-acid glycoprotein (AAG) and binding to AAG is saturable.

    US Natl Inst Health; DailyMed. Current Medication Information for ERIVEDGE (vismodegib) capsule (January 2012). Available from, as of March 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a

    The single dose absolute bioavailability of vismodegib is 31.8%. Absorption is saturable as evidenced by the lack of dose proportional increase in exposure after a single dose of 270 mg or 540 mg vismodegib. Erivedge capsule may be taken without regard to meals because the systemic exposure of vismodegib at steady state is not affected by food.

    US Natl Inst Health; DailyMed. Current Medication Information for ERIVEDGE (vismodegib) capsule (January 2012). Available from, as of March 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a

    Vismodegib and its metabolites are eliminated primarily by the hepatic route with 82% of the administered dose recovered in the feces and 4.4% recovered in urine.

    US Natl Inst Health; DailyMed. Current Medication Information for ERIVEDGE (vismodegib) capsule (January 2012). Available from, as of March 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a

    While recent publications have suggested the pharmacokinetics (PK) of vismodegib appear to be non-linear, there has not been a report describing the mechanisms of non-linearity. This study provides evidence that two separate processes, namely, solubility-limited absorption and concentration-dependent plasma protein binding, can explain the non-linear PK of vismodegib. This study provides quantitative results which can account for the lower than expected accumulation of vismodegib with continuous daily dosing. Vismodegib has demonstrated clinical activity in patients with advanced basal cell carcinoma. The pharmacokinetics (PK) of vismodegib are non-linear. The objective of this study was to determine whether vismodegib PK change following repeated dosing by administering a tracer intravenous (iv) dose of (14) C-vismodegib with single and multiple oral doses. Healthy post menopausal female subjects (n= 6/group) received either a single or daily 150 mg vismodegib oral dose with a (14) C-labelled 10 ug iv bolus dose administered 2 hr after the single or last oral dose (day 7). Plasma samples were assayed for vismodegib by LC-MS/MS and for (14) C-vismodegib by accelerator mass spectrometry. Following a single i.v. dose, mean clearance, volume of distribution and absolute bioavailability were 43.4 mL hr(-1) , 16.4 l and 31.8%, respectively. Parallel concentration-time profiles following single oral and i.v. administration of vismodegib indicated elimination rate limited PK. Following iv administration at steady-state, mean clearance and volume of distribution were 78.5 mL hr(-1) and 26.8 L, respectively. Comparison of iv PK parameters after single and multiple oral dosing showed similar half-life, increased clearance and volume of distribution (81% and 63% higher, respectively) and decreased bioavailability (77% lower) after repeated dosing. Relative to single dose, the unbound fraction of vismodegib increased 2.4-fold with continuous daily dosing. Vismodegib exhibited a long terminal half-life after oral and iv administration, moderate absolute bioavailability and non-linear PK after repeated dosing. Results from this study suggest that the non-linear PK of vismodegib result from two separate, non-linear processes, namely solubility limited absorption and high affinity, saturable plasma protein binding.

    PMID:22458643 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495143 Graham RA et al; Br J Clin Pharmacol 74 (5): 788-96 (2012)

    For more Absorption, Distribution and Excretion (Complete) data for Vismodegib (7 total), please visit the HSDB record page.

    5.5 Metabolism/Metabolites

    The main metabolic enzymes are CYP2C9 and CYP3A4, however more than 98% of total systemic vismodegib is not metabolized. Metabolic pathways of vismodegib in humans include oxidation, glucuronidation, and pyridine ring cleavage. The two most abundant oxidative metabolites recovered in feces are produced in vitro by recombinant CYP2C9 and CYP3A4/5.

    Greater than 98% of the total circulating drug-related components are the parent drug. Metabolic pathways of vismodegib in humans include oxidation, glucuronidation, and pyridine ring cleavage. The two most abundant oxidative metabolites recovered in feces are produced in vitro by recombinant CYP2C9 and CYP3A4/5.

    US Natl Inst Health; DailyMed. Current Medication Information for ERIVEDGE (vismodegib) capsule (January 2012). Available from, as of March 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a

    2-Chloro-N-(4-chloro-3-(pyridin-2-yl)-phenyl)-4-(methylsulfonyl)-benzamide (GDC-0449, vismodegib) is a potent and selective first-in-class small-molecule inhibitor of the Hedgehog signaling pathway and is currently in clinical development. In this study, we investigated the metabolic fate and disposition of GDC-0449 in rats and dogs after a single oral administration of (14)C-GDC-0449. ... GDC-0449 underwent extensive metabolism in rats and dogs with the major metabolic pathways being oxidation of the 4-chloro-3-(pyridin-2-yl)-phenyl moiety followed by phase II glucuronidation or sulfation. Three other metabolites resulting from an uncommon pyridine ring opening were found, mainly in feces, representing 1.7 to 17.7% of the dose in total in rats and dogs. ...

    PMID:21363998 Yue Q et al; Drug Metab Dispos 39 (6): 952-65 (2011)

    ... Proposed metabolites from exploratory metabolite identification in vitro (rat, dog and human liver microsomes) and in vivo (dog and rat urine) include three primary oxidative metabolites (M1-M3) and three sequential glucuronides (M4-M6). Oxidative metabolites identified in microsomes M1 and M3 were formed primarily by P4503A4/5 (M1) and P4502C9 (M3). GDC-0449 was not a potent inhibitor of P4501A2, P4502B6, P4502D6, and P4503A4/5 with IC50 estimates greater than 20 uM. K(i)'s estimated for P4502C8, P4502C9 and P4502C19 and were 6.0, 5.4 and 24 uM, respectively. An evaluation with Simcyp suggests that GDC-0449 has a low potential of inhibiting P4502C8 and P4502C9. Furthermore, GDC-0449 (15 uM) was not a potent P-glycoprotein/ABCB1 inhibitor in MDR1-MDCK cells.

    PMID:19845436 Wong H et al; Xenobiotica 39 (11): 850-61 (2009)

    5.6 Biological Half-Life

    The half-life after a single dose is 12 days, and after continuous daily dosing is 4 days.

    The estimated elimination half-life of vismodegib is 4 days after continuous once-daily dosing and 12 days after a single dose.

    US Natl Inst Health; DailyMed. Current Medication Information for ERIVEDGE (vismodegib) capsule (January 2012). Available from, as of March 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a

    5.7 Mechanism of Action

    Mutations of the Hedgehog pathway may results in uncontrolled proliferation of skin basal cells. Vismodegib binds to and inhibits the transmembrane protein Smoothened homologue (SMO) to inhibit the Hedgehog signalling pathway.

    Vismodegib is an inhibitor of the Hedgehog pathway. Vismodegib binds to and inhibits Smoothened, a transmembrane protein involved in Hedgehog signal transduction.

    US Natl Inst Health; DailyMed. Current Medication Information for ERIVEDGE (vismodegib) capsule (January 2012). Available from, as of March 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a

    Recent evidence from in vitro and in vivo studies has demonstrated that aberrant reactivation of the Sonic Hedgehog (SHH) signaling pathway regulates genes that promote cellular proliferation in various human cancer stem cells (CSCs). Therefore, the chemotherapeutic agents that inhibit activation of Gli transcription factors have emerged as promising novel therapeutic drugs for pancreatic cancer. GDC-0449 (Vismodegib), orally administrable molecule belonging to the 2-arylpyridine class, inhibits SHH signaling pathway by blocking the activities of Smoothened. The objectives of this study were to examine the molecular mechanisms by which GDC-0449 regulates human pancreatic CSC characteristics in vitro. GDC-0499 inhibited cell viability and induced apoptosis in three pancreatic cancer cell lines and pancreatic CSCs. This inhibitor also suppressed cell viability, Gli-DNA binding and transcriptional activities, and induced apoptosis through caspase-3 activation and PARP cleavage in pancreatic CSCs. GDC-0449-induced apoptosis in CSCs showed increased Fas expression and decreased expression of PDGFRa. Furthermore, Bcl-2 was down-regulated whereas TRAIL-R1/DR4 and TRAIL-R2/DR5 expression was increased following the treatment of CSCs with GDC-0449. Suppression of both Gli1 plus Gli2 by shRNA mimicked the changes in cell viability, spheroid formation, apoptosis and gene expression observed in GDC-0449-treated pancreatic CSCs. Thus, activated Gli genes repress DRs and Fas expressions, up-regulate the expressions of Bcl-2 and PDGFRa and facilitate cell survival. These data suggest that GDC-0499 can be used for the management of pancreatic cancer by targeting pancreatic CSCs.

    PMID:22087285 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210776 Singh BN et al; PLoS One. 2011;6(11):e27306. doi: 10.1371/journal.pone.0027306. Epub 2011

    Hedgehog (Hh) signaling is involved in the pathogenesis of liver fibrosis. It has been previously shown that Hh-inhibitor cyclopamine (CYA) can reduce liver fibrosis in rats. However, CYA is not stable in vivo, which limits its clinical application. This study compares the antifibrotic potential of two known Hh antagonists, vismodegib (GDC-0449, abbreviated to GDC) and CYA. GDC is a synthetic molecule presently in clinical cancer trials and has been reported to be safe and efficacious. These drugs attenuated early liver fibrosis in common bile duct ligated rats, improved liver function, and prevented hepatic stellate cell (HSC) activation, thereby suppressing epithelial to mesenchymal transition (EMT). While both CYA and GDC increased the number of proliferating cell nuclear antigen positive liver cells in vivo, only CYA increased Caspase-3 expression in HSCs in rat livers, suggesting that while GDC and CYA effectively attenuate early liver fibrosis, their hepatoprotective effects may be mediated through different modes of action. Thus, GDC has the potential to serve as a new therapeutic agent for treating early liver fibrosis.

    PMID:22994359 Pratap A et al; J Drug Target 20 (9): 770-82 (2012)

    API SUPPLIERS

    read-more
    read-more

    01

    Polpharma

    Poland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    World ADC London
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothPolpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Contact Supplier Contact Supplier
    Flag Poland
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Polpharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Fermion Oy

    Finland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    DCAT Week
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothWith Fermion, start the journey of your innovative API.

    Contact Supplier Contact Supplier
    Flag Finland
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    fermion

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Omgene Life Sciences Pvt. Ltd

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pittcon 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Omgene Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Arevipharma

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Pittcon 2025
    Not Confirmed
    arrow

    05

    Deva Holding AS

    Turkey

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Pittcon 2025
    Not Confirmed
    arrow

    06

    Hebei Huarong Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Pittcon 2025
    Not Confirmed
    arrow

    07

    Hetero Drugs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Pittcon 2025
    Not Confirmed
    arrow

    Hetero Drugs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pittcon 2025
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Alembic Pharmaceuticals Limited

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Pittcon 2025
    Not Confirmed
    arrow

    09

    DEAFARMA

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Pittcon 2025
    Not Confirmed
    arrow

    DEAFARMA

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pittcon 2025
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Suppliers

    read-more
    read-more

    01

    Polpharma

    Poland
    arrow
    World ADC London
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothPolpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Contact Supplier Contact Supplier
    Flag Poland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Vismodegib

    About the Company : Polpharma API, part of a leading Polish pharmaceutical group, has over 70 years of experience in process development and cGMP manufacturing. We offer end-to-end solutions, from API...

    Polpharma API, part of a leading Polish pharmaceutical group, has over 70 years of experience in process development and cGMP manufacturing. We offer end-to-end solutions, from API development to scale-up, at our FDA-approved plant in Central Europe. Our expert team provides high-quality, tailor-made services for small molecule API clinical candidates, with strong regulatory support and world-class facilities. Trusted by global partners, we specialize in complex chemical processes and deliver exceptional customer experiences. Polpharma API – Your reliable European CDMO partner.
    Polpharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Fermion Oy

    Finland
    arrow
    DCAT Week
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothWith Fermion, start the journey of your innovative API.

    Contact Supplier Contact Supplier
    Flag Finland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Vismodegib

    About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & F...

    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
    fermion

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Omgene Life Sciences Pvt. Ltd

    India
    arrow
    Pittcon 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Vismodegib

    About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...

    Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines.
    Omgene Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Alembic Pharmaceuticals Limited

    India
    Pittcon 2025
    Not Confirmed
    arrow

    Alembic Pharmaceuticals Limited

    India
    arrow
    Pittcon 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Vismodegib

    About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

    Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Arevipharma

    Germany
    Pittcon 2025
    Not Confirmed
    arrow

    Arevipharma

    Germany
    arrow
    Pittcon 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Vismodegib

    About the Company : Arevipharma GmbH is a modern manufacturer of active pharmaceutical ingredients and intermediates with more than 140 years of expertise. Our customers are generic and research-based...

    Arevipharma GmbH is a modern manufacturer of active pharmaceutical ingredients and intermediates with more than 140 years of expertise. Our customers are generic and research-based pharmaceutical companies on five continents. Our business partners recognise us as a competent, reliable and efficient company that is distinguished by individual service and an innovative character. The company’s 140 year history is based on the knowledge, skills, commitment and loyalty of its employees. Arevipharma also feels committed to its owners and investors. Due to the consistent expansion of new technologies,
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    DEAFARMA

    Italy
    Pittcon 2025
    Not Confirmed
    arrow

    DEAFARMA

    Italy
    arrow
    Pittcon 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Hhantag691

    About the Company : In the dinamic pharmaceutical field, DEAFARMA is the reference point for primaries Pharmaceutical Laboratories for over twenty years, even in the national and international territo...

    In the dinamic pharmaceutical field, DEAFARMA is the reference point for primaries Pharmaceutical Laboratories for over twenty years, even in the national and international territory. DEAFARMA works with success in the pharmaceutical raw materials field through Agencies and professional relations with the most important European and Asiatic factories. Our partners are well known, reliable producers and all of them are operating in accordance with the latest GMP Rules. The APIs mentioned in the DEAFARMA catalogue are always supported by DMF and/or CEP.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Deva Holding AS

    Turkey
    Pittcon 2025
    Not Confirmed
    arrow

    Deva Holding AS

    Turkey
    arrow
    Pittcon 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Turkey
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Vismodegib

    About the Company : Active since in 1958, DEVA is one of the deep-rooted medicine manufacturers of Turkey. With its main scope of business covering manufacturing and marketing of medicines for human u...

    Active since in 1958, DEVA is one of the deep-rooted medicine manufacturers of Turkey. With its main scope of business covering manufacturing and marketing of medicines for human use and raw materials, DEVA also produces veterinary drugs, cologne and medical vials. DEVA has been creating difference by releasing new products into market every single year. DEVA places puts emphasize on research and development activities so as to facilitate access by the patients to the medicines they could need. On this respect, at Deva quality comes first. Regular FDA&EU audits enabled us to register and sell our products in the US&Eu market.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Hebei Huarong Pharmaceutical

    China
    Pittcon 2025
    Not Confirmed
    arrow

    Hebei Huarong Pharmaceutical

    China
    arrow
    Pittcon 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Vismodegib

    About the Company : Hebei Huarong Pharmaceutical Co., Ltd (HRPC) is jointly invested by CSPC and Taoyuan Group, CSPC send people for administration. The company was established in 1993, which is mainl...

    Hebei Huarong Pharmaceutical Co., Ltd (HRPC) is jointly invested by CSPC and Taoyuan Group, CSPC send people for administration. The company was established in 1993, which is mainly engaged in manufacturing and marketing Vitamin B12, feed additive and acarbose. After nearly 20 years of development, HRPC has developed into an influential and professional producer. HRPC has full range of products and superb quality, more than 80% of the products export to abroad. HRPC is credited as the export-oriented and technique-advanced enterprise in Hebei province.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Hetero Drugs

    India
    Pittcon 2025
    Not Confirmed
    arrow

    Hetero Drugs

    India
    arrow
    Pittcon 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Vismodegib

    About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...

    Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs. Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"VISMODEGIB","year":"2021","qtr":"Q1","strtotime":1616005800,"product":"VISMODEGIB (GROUP:B) (TAX INVOICE NO:190 5205311 DATE:16.03.2021","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"GULF AGENCY COMPANY ","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"39548.7","totalValueFC":"39140.5","currency":"USD","unitRateINR":2849480,"date":"18-Mar-2021","totalValueINR":"2849480","totalValueInUsd":"39140.5","indian_port":"HYDERABAD AIR","hs_no":"29339910","bill_no":"9459799","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1733941800,"product":"VISMODEGIB","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"GULF AGENCY COMPANY DUBAI LLC","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"31680","totalValueFC":"31211","currency":"USD","unitRateINR":2651967,"date":"12-Dec-2024","totalValueINR":"2651967","totalValueInUsd":"31211","indian_port":"Hyderabad Air","hs_no":"29339910","bill_no":"6405483","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1738261800,"product":"VISMODEGIB","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"BASLE","customer":"AIRPHARM","customerCountry":"SWITZERLAND","quantity":"0.40","actualQuantity":"0.4","unit":"KGS","unitRateFc":"31680","totalValueFC":"12442.5","currency":"USD","unitRateINR":2682264.5,"date":"31-Jan-2025","totalValueINR":"1072905.8","totalValueInUsd":"12442.5","indian_port":"Hyderabad Air","hs_no":"29339910","bill_no":"7775350","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""}]
    18-Mar-2021
    31-Jan-2025
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Stamford Pharmaceuticals Announces First Patient Treated with SP-002 in Phase 2 BCC Study

    Details:

    SP-002 is an adenovirus-based biologic producing Interferon-g, under investigation with vismodegib for locally advanced metastatic basal cell carcinoma.


    Lead Product(s): SP-002,Vismodegib

    Therapeutic Area: Oncology Brand Name: SP-002

    Study Phase: Phase IIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 11, 2024

    blank

    01

    Stamford Pharmaceuticals

    U.S.A
    arrow
    Natural Products Expo
    Not Confirmed

    Stamford Pharmaceuticals

    U.S.A
    arrow
    Natural Products Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SP-002,Vismodegib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Stamford Pharmaceuticals Announces First Patient Treated with SP-002 in Phase 2 BCC Study

    Details : SP-002 is an adenovirus-based biologic producing Interferon-g, under investigation with vismodegib for locally advanced metastatic basal cell carcinoma.

    Product Name : SP-002

    Product Type : Large molecule

    Upfront Cash : Not Applicable

    April 11, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Granulation

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Parenteral

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Topical

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Looking for 879085-55-9 / Vismodegib API manufacturers, exporters & distributors?

    Vismodegib manufacturers, exporters & distributors 1

    86

    PharmaCompass offers a list of Vismodegib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vismodegib manufacturer or Vismodegib supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vismodegib manufacturer or Vismodegib supplier.

    PharmaCompass also assists you with knowing the Vismodegib API Price utilized in the formulation of products. Vismodegib API Price is not always fixed or binding as the Vismodegib Price is obtained through a variety of data sources. The Vismodegib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Vismodegib

    Synonyms

    879085-55-9, Gdc-0449, Erivedge, 2-chloro-n-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Vismodegib (gdc-0449), Hhantag691

    Cas Number

    879085-55-9

    Unique Ingredient Identifier (UNII)

    25X868M3DS

    About Vismodegib

    Vismodegib is an orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.

    Vismodegib Manufacturers

    A Vismodegib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vismodegib, including repackagers and relabelers. The FDA regulates Vismodegib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vismodegib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Vismodegib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Vismodegib Suppliers

    A Vismodegib supplier is an individual or a company that provides Vismodegib active pharmaceutical ingredient (API) or Vismodegib finished formulations upon request. The Vismodegib suppliers may include Vismodegib API manufacturers, exporters, distributors and traders.

    click here to find a list of Vismodegib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Vismodegib GMP

    Vismodegib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Vismodegib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vismodegib GMP manufacturer or Vismodegib GMP API supplier for your needs.

    Vismodegib CoA

    A Vismodegib CoA (Certificate of Analysis) is a formal document that attests to Vismodegib's compliance with Vismodegib specifications and serves as a tool for batch-level quality control.

    Vismodegib CoA mostly includes findings from lab analyses of a specific batch. For each Vismodegib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Vismodegib may be tested according to a variety of international standards, such as European Pharmacopoeia (Vismodegib EP), Vismodegib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vismodegib USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search